Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-MAG (AA 20-516) Recombinant Antibody (CBFYM-1293) (CBMAB-M1452-FY)


See all MAG antibodies
Online Inquiry

Summary

Host Animal
Mouse
Specificity
Rat
Clone
CBFYM-1293
Antibody Isotype
IgG1
Application
ELISA, WB

Basic Information

Immunogen
Recombinant corresponding to aa20-516 of rat MAG expresessed in NS0 cells
Specificity
Rat
Antibody Isotype
IgG1
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Lyophilized
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Epitope
AA 20-516

Target

Full Name
Myelin Associated Glycoprotein
Introduction
The protein encoded by this gene is a type I membrane protein and member of the immunoglobulin superfamily. It is thought to be involved in the process of myelination. It is a lectin that binds to sialylated glycoconjugates and mediates certain myelin-neuron cell-cell interactions. Three alternatively spliced transcripts encoding different isoforms have been described for this gene.
Entrez Gene ID
29409
UniProt ID
P07722
Alternative Names
Myelin Associated Glycoprotein; Sialic Acid Binding Ig-Like Lectin 4A; SIGLEC-4A; GMA; Sialic Acid-Binding Immunoglobulin-Like Lectin 4A; Myelin-Associated Glycoprotein; SIGLEC4A; S-MAG; SPG75
Function
Adhesion molecule that mediates interactions between myelinating cells and neurons by binding to neuronal sialic acid-containing gangliosides and to the glycoproteins RTN4R and RTN4RL2 (By similarity).
Not required for initial myelination, but seems to play a role in the maintenance of normal axon myelination. Protects motoneurons against apoptosis, also after injury; protection against apoptosis is probably mediated via interaction with neuronal RTN4R and RTN4RL2. Required to prevent degeneration of myelinated axons in adults; this probably depends on binding to gangliosides on the axon cell membrane (By similarity).
Negative regulator of neurite outgrowth; in dorsal root ganglion neurons the inhibition is mediated primarily via binding to neuronal RTN4R or RTN4RL2 and to a lesser degree via binding to neuronal gangliosides. In cerebellar granule cells the inhibition is mediated primarily via binding to neuronal gangliosides. In sensory neurons, inhibition of neurite extension depends only partially on RTN4R, RTN4RL2 and gangliosides. Inhibits axon longitudinal growth (By similarity).
Inhibits axon outgrowth by binding to RTN4R (By similarity).
Preferentially binds to alpha-2,3-linked sialic acid. Binds ganglioside Gt1b (By similarity).
Biological Process
Axon regenerationIEA:Ensembl
Cell adhesionISS:UniProtKB
Cell-cell adhesion via plasma-membrane adhesion moleculesISS:UniProtKB
Cellular response to mechanical stimulusIEA:Ensembl
Central nervous system myelin formationIEA:Ensembl
Negative regulation of axon extensionISS:UniProtKB
Negative regulation of neuron apoptotic processISS:UniProtKB
Negative regulation of neuron differentiationIEA:Ensembl
Negative regulation of neuron projection developmentISS:UniProtKB
Positive regulation of astrocyte differentiationIEA:Ensembl
Positive regulation of myelinationIEA:Ensembl
Substantia nigra developmentHEP:UniProtKB
Transmission of nerve impulseIEA:Ensembl
Cellular Location
Cell membrane
Membrane raft
Involvement in disease
Spastic paraplegia 75, autosomal recessive (SPG75):
A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG75 is characterized by onset in early childhood and is associated with mild to moderate cognitive impairment.
Topology
Extracellular: 20-516
Helical: 517-536
Cytoplasmic: 537-626
PTM
N-glycosylated.
Phosphorylated on tyrosine residues.
Ubiquitinated, leading to proteasomal degradation.
More Infomation

Stino, A. M., Elsheikh, B., & Allen, J. A. (2023). Anti–myelin‐associated glycoprotein neuropathy: Where do we stand?. Muscle & Nerve, 68(6), 823-832.

Doneddu, P. E., Ruiz, M., Bianchi, E., Liberatore, G., Manganelli, F., Cocito, D., ... & Nobile‐Orazio, E. (2023). A diagnostic score for anti‐myelin‐associated‐glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti‐myelin‐associated‐glycoprotein antibody. European journal of neurology, 30(2), 501-510.

Mariotto, S., De Gaspari, P., Jäger, D., Hahn, S., Forni, C., Saschenbrecker, S., ... & Ferrari, S. (2023). A novel cell-based immunofluorescence assay for the detection of autoantibodies to myelin-associated glycoprotein. Frontiers in Neurology, 14.

Sato, R., Shimizu, F., Kuwahara, M., Mizukami, Y., Watanabe, K., Maeda, T., ... & Kanda, T. (2023). Autocrine TNF-α Increases Penetration of Myelin-Associated Glycoprotein Antibodies Across the Blood-Nerve Barrier in Anti-MAG Neuropathy. Neurology-Neuroimmunology Neuroinflammation, 10(3).

Vivinetto, A. L., Castañares, C., Garcia-Keller, C., Moyano, A. L., Falcon, C., Palandri, A., ... & Lopez, P. H. (2022). Myelin-associated glycoprotein activation triggers glutamate uptake by oligodendrocytes in vitro and contributes to ameliorate glutamate-mediated toxicity in vivo. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1868(4), 166324.

Latov, N. (2021). Antibody testing in neuropathy associated with anti-Myelin-Associated Glycoprotein antibodies: Where we are after 40 years. Current Opinion in Neurology, 34(5), 625-630.

Khajenobar, N. B., Mahboob, S., Nourazarian, A., Shademan, B., Laghousi, D., Moayed, Z. B., ... & Nikanfar, M. (2021). Comparison between cerebrospinal fluid and serum levels of myelin-associated glycoprotein, total antioxidant capacity, and 8-hydroxy-2′-deoxyguanosine in patients with multiple sclerosis. Clinical Neurology and Neurosurgery, 200, 106377.

Minnema, M. C., Vos, J., Eftimov, F., & Vrancken, A. (2021). P-034: MAGNAZ trial-a prospective phase II study in patients with monoclonal gammopathy of unknown significance (MGUS) and anti-myelin associated glycoprotein (MAG) neuropathy and zanubrutinib treatment. Clinical Lymphoma Myeloma and Leukemia, 21, S57.

Cawley, J. L., Jordan, L. R., & Wittenberg, N. J. (2020). Detection and characterization of vesicular gangliosides binding to myelin-associated glycoprotein on supported lipid bilayers. Analytical Chemistry, 93(2), 1185-1192.

Takai, Y., Misu, T., Kaneko, K., Chihara, N., Narikawa, K., Tsuchida, S., ... & Japan MOG-antibody Disease Consortium Otsuka Yoshihisa Nishimaki Keiichi Ishigaki Sho Yoshida Kazunari Iguchi Yasuyuki Fukuda Takahiro Nohara Seitaro Tamaoka Akira Fujimori Juichi. (2020). Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain, 143(5), 1431-1446.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-MAG (AA 20-516) Recombinant Antibody (CBFYM-1293)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quote Online Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry